The Immunology Core will be co-directed by Andrew Luster and Shiv Pillai. A variety of services will be provided by the Core. These include a number of novel and powerful approaches that can be applied to human immunology, for which the Core offers protocols, education, and bioinformatics analysis. In addition to these more innovative approaches, the Core also continues to provide access to established technologies such as high-speed cell sorting and cytokine assays. The services are organized into three major categories: (1) education and training, (2) routine immunology tools, and (3) specialized immunology services. By assisting investigators in developing assays and offering access to both standard techniques and a number of newly developing, powerful immunologic techniques, this core is fundamentally necessary for a number of studies pursued by CSIBD investigators and advanced trainees ready to emerge as independent investigators.
The specific aims of Immunology Core are to (1) provide CSIBD members with access to immunological resources that would otherwise be cost-prohibitive to individual researchers; (2) offer CSIBD investigators access to cutting-edge immunological techniques that are at the forefront of immunology research; and (3) promote the development of junior investigators and foster collaborations by providing a connection point between investigators of varying research approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK043351-28
Application #
9399649
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
28
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Gevers, Dirk; Kugathasan, Subra; Knights, Dan et al. (2017) A Microbiome Foundation for the Study of Crohn's Disease. Cell Host Microbe 21:301-304
Molinie, Benoit; Giallourakis, Cosmas C (2017) Genome-Wide Location Analyses of N6-Methyladenosine Modifications (m6A-Seq). Methods Mol Biol 1562:45-53
Schwerd, Tobias; Pandey, Sumeet; Yang, Huei-Ting et al. (2017) Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut 66:1060-1073
Maehara, Takashi; Mattoo, Hamid; Ohta, Miho et al. (2017) Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76:377-385
Jung, Keehoon; Heishi, Takahiro; Khan, Omar F et al. (2017) Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest 127:3039-3051
Rooks, Michelle G; Veiga, Patrick; Reeves, Analise Z et al. (2017) QseC inhibition as an antivirulence approach for colitis-associated bacteria. Proc Natl Acad Sci U S A 114:142-147
Ananthakrishnan, Ashwin N; Luo, Chengwei; Yajnik, Vijay et al. (2017) Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 21:603-610.e3
Canali, Susanna; Zumbrennen-Bullough, Kimberly B; Core, Amanda B et al. (2017) Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405-414
Ananthakrishnan, A N; Sakuraba, A; Barnes, E L et al. (2017) The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 46:162-168
Miyabe, Chie; Miyabe, Yoshishige; Strle, Klemen et al. (2017) An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 76:898-905

Showing the most recent 10 out of 1056 publications